These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24682088)

  • 1. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy.
    Kuo YH; Lu SN; Chen CH; Chang KC; Hung CH; Tai WC; Tsai MC; Tseng PL; Hu TH; Wang JH
    PLoS One; 2014; 9(3):e93160. PubMed ID: 24682088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B.
    Lim SG; Cho SW; Lee YC; Jeon SJ; Lee MH; Cho YJ; Kim SS; Kim YB; Seok JY; Cheong JY; Kim JH
    Hepatogastroenterology; 2011; 58(106):539-45. PubMed ID: 21661428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study.
    Dong XQ; Wu Z; Li J; Wang GQ; Zhao H;
    J Gastroenterol Hepatol; 2019 Apr; 34(4):755-763. PubMed ID: 30290019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.
    Kong Y; Sun Y; Zhou J; Wu X; Chen Y; Piao H; Lu L; Ding H; Nan Y; Jiang W; Xu Y; Xie W; Li H; Feng B; Shi G; Chen G; Li H; Zheng H; Cheng J; Wang T; Liu H; Lv F; Shao C; Mao Y; Sun J; Chen T; Han T; Han Y; Wang L; Ou X; Zhang H; Jia J; You H
    J Viral Hepat; 2019 May; 26(5):576-585. PubMed ID: 30624000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents.
    Kim JK; Ma DW; Lee KS; Paik YH
    J Korean Med Sci; 2014 Apr; 29(4):570-5. PubMed ID: 24753706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse correlations between fibrosis-related factors and liver stiffness measurement by transient elastography in chronic hepatitis B.
    Lin Z; Liang J; Zhu J; Hu C; Gu Y; Lai J; Zheng Y; Gao Z
    Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):217-225. PubMed ID: 29194232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.
    Fu X; Lou H; Chen F; Gao X; Lin Z
    Clin Exp Med; 2020 May; 20(2):241-248. PubMed ID: 32052245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
    Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal change of liver stiffness by transient elestography in chronic hepatitis B patients treated with nucleos(t)ide analogue.
    Jang W; Yu SI; Sinn DH; Park SH; Park H; Park JY; Jeon TJ; Oh TH; Shin WC; Choi WC
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):195-200. PubMed ID: 24231289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment.
    Wu SD; Liu LL; Cheng JL; Liu Y; Cheng LS; Wang SQ; Ma W; Chen LP; Tseng YJ; Wang JY; Shen XZ; Jiang W
    Clin Exp Med; 2018 Aug; 18(3):433-443. PubMed ID: 29696462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study.
    Fung J; Lai CL; Wong DK; Seto WK; Hung I; Yuen MF
    J Viral Hepat; 2011 Jul; 18(7):e200-5. PubMed ID: 21692933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase.
    Tan YW; Zhou XB; Ye Y; He C; Ge GH
    World J Gastroenterol; 2017 Aug; 23(31):5746-5754. PubMed ID: 28883700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir.
    Zhao K; Yang T; Sun M; Zhang W; An Y; Chen G; Jin L; Shang Q; Song W
    Mol Cells; 2017 Jun; 40(6):418-425. PubMed ID: 28614914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients.
    Wong GL; Wong VW; Choi PC; Chan AW; Chim AM; Yiu KK; Chu SH; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2011; 16(2):165-72. PubMed ID: 21447865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver stiffness measurement in cirrhotic patient -- implications of disease activity and treatment efficacy.
    Xu HW; Lu SN; Hung CH; Chang KC; Hu TH; Wang JH
    Kaohsiung J Med Sci; 2012 Dec; 28(12):641-8. PubMed ID: 23217355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exploring the effects of entecavir treatment on the degree of liver fibrosis in patients with non-alcoholic fatty liver combined with chronic hepatitis B in Tibet region].
    Wen QP; Qian H; Ba S; Lu MJ; Silang LDJ; Shi L
    Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):304-308. PubMed ID: 35462487
    [No Abstract]   [Full Text] [Related]  

  • 17. [Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses].
    Yang NH; Yuan GS; Zhou YC; Liu JW; Huang HP; Hu CG; Xiong L; Li Y; Zhou FY; Yang SL; Zhou YP
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun; 36(6):775-9. PubMed ID: 27320877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy.
    Li Q; Chen L; Zhou Y
    Clin Exp Med; 2018 May; 18(2):273-282. PubMed ID: 29350286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens.
    Liu C; Wu W; Shang S; Huang E; Xun Z; Lin J; Chen T; Yang B; Chen J; Ou Q
    J Med Virol; 2019 Feb; 91(2):249-257. PubMed ID: 30011350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment.
    Li X; Jin Q; Xu H; Zhang Z; Zhou H; Yan D; Li D; Gao P; Niu J
    Exp Ther Med; 2017 Jun; 13(6):3624-3630. PubMed ID: 28588691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.